UY39127A - Materiales y métodos para modular la inmunidad mediada por cadena delta - Google Patents

Materiales y métodos para modular la inmunidad mediada por cadena delta

Info

Publication number
UY39127A
UY39127A UY0001039127A UY39127A UY39127A UY 39127 A UY39127 A UY 39127A UY 0001039127 A UY0001039127 A UY 0001039127A UY 39127 A UY39127 A UY 39127A UY 39127 A UY39127 A UY 39127A
Authority
UY
Uruguay
Prior art keywords
methods
materials
antibodies
delta chain
immunity mediated
Prior art date
Application number
UY0001039127A
Other languages
English (en)
Inventor
Sanjaya Singh
Rajkumar Ganesan
S Grewal Iqbal
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY39127A publication Critical patent/UY39127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen anticuerpos multiespecíficos anti-TRDV2 o fragmentos de unión a antígeno de los mismos . También se describen los ácidos nucleicos que codifican los anticuerpos, las composiciones que comprenden los anticuerpos, los métodos para producir los anticuerpos y los métodos para usar los anticuerpos para tratar o prevenir enfermedades.
UY0001039127A 2020-03-13 2021-03-12 Materiales y métodos para modular la inmunidad mediada por cadena delta UY39127A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062989111P 2020-03-13 2020-03-13

Publications (1)

Publication Number Publication Date
UY39127A true UY39127A (es) 2021-09-30

Family

ID=77664333

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039127A UY39127A (es) 2020-03-13 2021-03-12 Materiales y métodos para modular la inmunidad mediada por cadena delta

Country Status (11)

Country Link
US (1) US20210284730A1 (es)
EP (1) EP4118121A4 (es)
JP (1) JP2023518189A (es)
KR (1) KR20220154190A (es)
CN (1) CN115605512A (es)
AU (1) AU2021234327A1 (es)
CA (1) CA3175134A1 (es)
IL (1) IL296358A (es)
TW (1) TW202144416A (es)
UY (1) UY39127A (es)
WO (1) WO2021183845A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
US12077586B2 (en) 2018-09-19 2024-09-03 LAVA Therapeutics N.V. Bispecific antibodies for use in the treatment of hematological malignancies
CA3199767A1 (en) 2020-10-28 2022-05-05 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273713T1 (de) * 1996-10-31 2004-09-15 Mochida Pharm Co Ltd Fas-antagonist für die prophylaxe oder therapie von gvhd
SI2794658T1 (sl) * 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
CN108350076B (zh) * 2015-08-17 2022-06-07 詹森药业有限公司 抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
HUE064791T2 (hu) * 2015-11-25 2024-04-28 Visterra Inc APRIL ellenes antitest molekulák és alkalmazásaik
CN118421557A (zh) * 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物
KR20210011002A (ko) * 2018-05-16 2021-01-29 얀센 바이오테크 인코포레이티드 암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법

Also Published As

Publication number Publication date
AU2021234327A1 (en) 2022-10-06
CA3175134A1 (en) 2021-09-16
IL296358A (en) 2022-11-01
US20210284730A1 (en) 2021-09-16
CN115605512A (zh) 2023-01-13
KR20220154190A (ko) 2022-11-21
JP2023518189A (ja) 2023-04-28
EP4118121A1 (en) 2023-01-18
TW202144416A (zh) 2021-12-01
EP4118121A4 (en) 2024-05-15
WO2021183845A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
UY39127A (es) Materiales y métodos para modular la inmunidad mediada por cadena delta
CY1122994T1 (el) Μεθοδος καθαρισμου κανναβινοειλων, συνθεσεων και kit αυτων
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
CO2021015998A2 (es) Materiales y métodos para modular la inmunidad mediada por células t
CO2021003900A2 (es) Moléculas de unión a antígeno biespecíficas que comprenden el clon 212 anti-fap
CO2019009432A2 (es) Nuevas moléculas de unión a antígeno biespecíficas capaces de unirse específicamente a cd40 y a fap.
AR110526A1 (es) Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
CL2019000836A1 (es) Construcciones de inmunoglobulina heterodiméricas y métodos de preparación de las mismas.
DOP2022000229A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
CO7061039A2 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
ECSP23025065A (es) Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
UY39415A (es) Métodos y composiciones para modular la inmunidad mediada por cadenas beta
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO7061040A2 (es) Anticuerpos contra la metaloproteinasa de la matriz 9
CY1125552T1 (el) Μεθοδος για την παρασκευη ουσιαστικα διαστερεομερικως καθαρου φωσφοροδιαμιδικου ολιγομερους, φωσφοροδιαμιδικου ολιγομερους που παρασκευαζεται με τετοια μεθοδο και φαρμακευτικη συνθεση αποτελουμενη απο τετοιο φωσφοροδιαμιδικο ολιγομερες
PE20230160A1 (es) Anticuerpos especificos para cd47, pd-l1 y sus usos
UY39416A (es) Moléculas de direccionamiento inmunes multiespecíficas y usos de estas
ECSP20042489A (es) Anticuerpos de cadena pesada que se unen a cd22
CO2022001222A2 (es) Materiales y métodos para fragmentos variables de cadena única mejorados
CO2019009815A2 (es) Combinaciones farmacéuticas
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
BR112022027101A2 (pt) Anticorpos multiespecíficos que se ligam a bcma
BR112021023956A2 (pt) Processo de etapa única para produzir um oleogel de proteína
UY39699A (es) Anticuerpos anti-tau y usos de estos
CL2024000248A1 (es) Composiciones y métodos para anticuerpos anti-pacap